ROIV - Roivant Sciences Ltd.
IEX Last Trade
11.98
-0.010 -0.083%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:30:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
22.93%
PREVIOUS CLOSE
CHG
CHG%
$11.99
-0.01
-0.08%
Fundamental analysis
17%
Profitability
0%
Dept financing
11%
Liquidity
75%
Performance
20%
Performance
5 Days
3.72%
1 Month
-3.69%
3 Months
1.95%
6 Months
10.80%
1 Year
10.19%
2 Year
58.94%
Key data
Stock price
$11.98
DAY RANGE
N/A - N/A
52 WEEK RANGE
$10.06 - $13.06
52 WEEK CHANGE
$3.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Matthew Gline
Region: US
Website: roivant.com
Employees: 860
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: roivant.com
Employees: 860
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom.
Recent news